Williams Lewis T

SEC Form 4 insider trading activity

Williams Lewis T has filed 2 SEC Form 4 filings (3 transaction rows) across 1 company, with disclosures dating back to 2026. 2 of those filings fall inside the rolling window. Most recent filing: Feb 18, 2026.

On the most recent filing, Williams Lewis T is listed as Director at Protagonist Therapeutics, Inc. Inside the rolling window, Williams Lewis T reported no open-market purchases and 1 open-market sale totaling $1.5M in PTGX.

Companies traded

Other insiders at PTGX

Insider Buying

$0

reported purchases (SEC code P)

Insider Selling

$1.5M

reported sales (SEC code S)

Companies

1

in the rolling window

Source
PTGX
Williams Lewis T
Sale$1.5MFeb 18SEC ↗
Showing 1–1 of 1
1 / 1

Frequently asked questions

How many SEC Form 4 filings has Williams Lewis T made?

Williams Lewis T has filed 2 SEC Form 4 filings (3 transaction rows) across 1 company since 2026.

Which companies does Williams Lewis T trade?

Williams Lewis T has filed SEC Form 4 disclosures for 1 company, including PTGX.

When was Williams Lewis T's most recent SEC Form 4 filing?

Williams Lewis T's most recent SEC Form 4 filing on Tracefour is dated Feb 18, 2026.

What is Williams Lewis T's total buy and sell value in the current window?

Inside the rolling retention window, Williams Lewis T bought $0 and sold $1.5M based on SEC Form 4 filings.

What was Williams Lewis T's largest disclosed transaction?

The largest disclosed transaction in the current window is a sale of 18,000 PTGX shares on 2026-02-17, worth $1.5M, per SEC Form 4 filings.